RU2697851C2 - Антиметаногенные композиции и их применение - Google Patents

Антиметаногенные композиции и их применение Download PDF

Info

Publication number
RU2697851C2
RU2697851C2 RU2017106896A RU2017106896A RU2697851C2 RU 2697851 C2 RU2697851 C2 RU 2697851C2 RU 2017106896 A RU2017106896 A RU 2017106896A RU 2017106896 A RU2017106896 A RU 2017106896A RU 2697851 C2 RU2697851 C2 RU 2697851C2
Authority
RU
Russia
Prior art keywords
weight
statin
modified release
lovastatin
pharmaceutical composition
Prior art date
Application number
RU2017106896A
Other languages
English (en)
Russian (ru)
Other versions
RU2017106896A (ru
RU2017106896A3 (enExample
Inventor
Марк ПИМЕНТЕЛЬ
Ручи МАТХУР
Стив КАНЗЕР
Винс УОЧЕР
Original Assignee
Седарс-Синаи Медикал Сентер
Синтетик Байолоджикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Седарс-Синаи Медикал Сентер, Синтетик Байолоджикс, Инк. filed Critical Седарс-Синаи Медикал Сентер
Publication of RU2017106896A publication Critical patent/RU2017106896A/ru
Publication of RU2017106896A3 publication Critical patent/RU2017106896A3/ru
Application granted granted Critical
Publication of RU2697851C2 publication Critical patent/RU2697851C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2017106896A 2014-08-13 2015-08-13 Антиметаногенные композиции и их применение RU2697851C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462036948P 2014-08-13 2014-08-13
US62/036,948 2014-08-13
US201462043649P 2014-08-29 2014-08-29
US201462043789P 2014-08-29 2014-08-29
US62/043,789 2014-08-29
US62/043,649 2014-08-29
US201562141355P 2015-04-01 2015-04-01
US62/141,355 2015-04-01
PCT/US2015/045140 WO2016025762A1 (en) 2014-08-13 2015-08-13 Anti-methanogenic compositions and uses thereof

Publications (3)

Publication Number Publication Date
RU2017106896A RU2017106896A (ru) 2018-09-13
RU2017106896A3 RU2017106896A3 (enExample) 2019-03-19
RU2697851C2 true RU2697851C2 (ru) 2019-08-21

Family

ID=55301332

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017106896A RU2697851C2 (ru) 2014-08-13 2015-08-13 Антиметаногенные композиции и их применение

Country Status (12)

Country Link
US (5) US9956292B2 (enExample)
EP (1) EP3179983A4 (enExample)
JP (1) JP6667526B2 (enExample)
KR (1) KR102425303B1 (enExample)
CN (1) CN106687107B (enExample)
AU (1) AU2015301596B2 (enExample)
BR (1) BR112017002761A2 (enExample)
CA (1) CA2955666A1 (enExample)
IL (1) IL250568B (enExample)
MX (1) MX2017001971A (enExample)
RU (1) RU2697851C2 (enExample)
WO (1) WO2016025762A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US11344501B2 (en) 2014-08-13 2022-05-31 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US12071673B2 (en) 2013-03-15 2024-08-27 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9744208B2 (en) 2013-03-15 2017-08-29 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
US10219518B2 (en) * 2015-09-18 2019-03-05 Environmental Intellectual Property, Inc. Inhibition of methanogenesis to control wood boring insects and pestilence
US20190277833A1 (en) * 2016-05-19 2019-09-12 Synthetic Biologics, Inc. Anti-methanogenic compositions
WO2017223177A1 (en) * 2016-06-21 2017-12-28 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses
AU2017378393B2 (en) * 2016-12-14 2023-03-09 Bt Bidco, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
CA3045666A1 (en) 2016-12-14 2018-06-21 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices
CN116712540A (zh) * 2016-12-14 2023-09-08 比奥拉治疗股份有限公司 使用整联蛋白抑制剂治疗胃肠道疾病
AU2018212273B2 (en) 2017-01-26 2023-12-21 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
JP2020525436A (ja) * 2017-06-21 2020-08-27 ミネルバ・ニューロサイエンシズ・インコーポレイテッド 胃耐性制御放出経口剤形
WO2020055270A1 (en) * 2018-09-10 2020-03-19 Argenta Innovation Limited Sustained release formulations in delivery devices
KR20220080130A (ko) * 2019-10-09 2022-06-14 알.피.쉐러 테크놀러지즈 엘엘씨 비-동물 소프트겔 캡슐 제제, 그의 제조 방법 및 사용 방법
US11529310B2 (en) 2020-12-08 2022-12-20 Ruminant Biotech Corp Limited Devices and methods for delivery of substances to animals
WO2023069904A1 (en) * 2021-10-19 2023-04-27 Cedars-Sinai Medical Center Daily fasting methane to detect intestinal methanogen overgrowth and monitor treatment response
EP4451900A4 (en) * 2021-12-23 2025-04-30 Fonterra Co-Operative Group Ltd Use of lactic acid bacteria to improve feed efficiency
WO2024006531A1 (en) 2022-07-01 2024-01-04 Arkea Bio Corp. Compositions and methods for reducing deleterious atmospheric gas emissions from flooded ecosystems
CN121712489A (zh) * 2023-08-15 2026-03-20 赢创运营有限公司 一种用于在回肠和结肠递送剂型的肠溶包衣硬壳胶囊
AU2024327436A1 (en) 2023-08-24 2026-03-05 Synergraze Inc. Methods and compositions for improving feed-efficiency in animals and reducing enteric methane emissions
US12448600B2 (en) 2023-08-24 2025-10-21 Synergraze Inc. Extraction of antimethanogenic compounds
WO2025039087A1 (en) 2023-08-24 2025-02-27 Synergraze Inc. Methods and compositions for improving feed-efficiency in animals and reducing enteric methane emissions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000180A2 (en) * 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
WO2014110090A1 (en) * 2013-01-08 2014-07-17 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US225202A (en) * 1880-03-02 Clothes-slide
GB423083A (en) 1934-05-22 1935-01-24 Hugh Edwin Johnstone Peake Improvements in and relating to the manufacture of fermented beverages and medicinalpreparations
JPS60133852A (ja) 1983-12-23 1985-07-17 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai 新規な納豆製品
DE3718638A1 (de) 1987-06-04 1988-12-22 Thomae Gmbh Dr K Neue phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH03275630A (ja) 1990-03-23 1991-12-06 Hayashikane Sangyo Kk 肝機能改善剤及び肝機能改善食品又は飲料
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
DK0724454T3 (da) 1993-10-19 2004-07-12 Commw Scient Ind Res Org Fremgangsmåde til forbedring af drövtyggerdyrs eller drövtyggerlignende dyrs udnyttelse af næringsstoffer
US5447850A (en) 1994-01-31 1995-09-05 Mccann; James L. Method of producing methane from organic waste
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
JP3010007B2 (ja) 1995-05-22 2000-02-14 ビオフェルミン製薬株式会社 配合下剤
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
GB9711962D0 (en) 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
CN1119154C (zh) 1998-01-20 2003-08-27 上海信谊药业有限公司 双歧三联活菌制剂及制备方法
US6368591B2 (en) 1998-05-15 2002-04-09 Shanghai Sine Pharmaceutical Corporation Ltd. Beneficial microbe composition, new protective materials for the microbes, method to prepare the same and uses thereof
US5985907A (en) 1998-08-12 1999-11-16 Health Research, Inc. Method for inhibiting growth of methanogens
US6328959B1 (en) 1998-09-18 2001-12-11 The United States Of America As Represented By The Secretary Of The Navy Intestinal hydrogen removal using hydrogen-metabolizing microbes
AU2161000A (en) * 1998-12-07 2000-06-26 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
WO2001032162A1 (en) 1999-11-03 2001-05-10 Howard J. Smith & Associates Pty Ltd Liver selective therapy
GB2371748B (en) 1999-11-08 2004-12-01 Andrx Corp HMG-COA reductase inhibitor extended release formulation
CN1330253C (zh) 2000-06-13 2007-08-08 荷兰联合利华有限公司 含有无活力乳酸杆菌的食物制品
US6299774B1 (en) 2000-06-26 2001-10-09 Jack L. Ainsworth Anaerobic digester system
AU2003273141B2 (en) 2002-05-20 2009-05-07 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
BR0312936B8 (pt) 2002-07-18 2021-07-27 Agricultural Research Council aditivo alimentício, método para melhorar desempenho de ruminantes, bem como método de isolamento de uma cultura biologicamente pura de um micro-organismo ruminal superior
US20040132806A1 (en) * 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
US20040132802A1 (en) 2002-09-03 2004-07-08 Jackie Butler Pharmaceutical formulations and methods for modified release of statin drugs
ITBO20020564A1 (it) 2002-09-06 2004-03-07 Alfa Wassermann Spa Bifidobatteri e preparazioni che li contengono.
US20070280949A1 (en) 2003-07-10 2007-12-06 Michelle Alfa Combination Therapy for Gastroenteric Diseases Caused by Microorganisms
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
AU2003289546A1 (en) 2003-12-16 2005-07-05 Uk Chemipharm Co., Ltd. Process for preparing simvastatin.
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
AU2005247195A1 (en) 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Localized controlled absorption of statins in the gastrointestinal tract for achieving high blood levels of statins
US20060111436A1 (en) 2004-11-23 2006-05-25 John Griffin Compositions and treatments for modulating kinase and/or HMG-CoA reductase
US20090233888A1 (en) 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
US20100048595A1 (en) 2005-03-23 2010-02-25 Washington University In St. Louis Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
WO2008151032A2 (en) 2007-05-31 2008-12-11 Washington University In St. Louis Arrays and methods comprising m. smithii gene products
WO2008151257A2 (en) * 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US7970905B2 (en) 2008-07-03 2011-06-28 International Business Machines Corporation Method, system and computer program product for server selection, application placement and consolidation planning of information technology systems
CN102369275A (zh) 2009-02-02 2012-03-07 卓莫赛尔公司 新型细胞系和方法
UY32802A (es) 2009-07-23 2011-01-31 Provimi Holding B V Composiciones para reducir la metanogénesis gastrointestinal en rumiantes
US20130230498A1 (en) 2010-02-16 2013-09-05 Arizona Board Of Regents For And On Behalf Of Arizona State University Reducing short-chain fatty acids and energy uptake in obese humans by managing their intestinal microbial communities
KR101298788B1 (ko) * 2011-03-15 2013-08-22 보령제약 주식회사 안정성이 개선된 복합제제
CN103230593A (zh) * 2012-10-30 2013-08-07 辽宁亿灵科创生物医药科技有限公司 一种治疗胃肠疾病的药物组合物
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法
US9289418B2 (en) 2013-03-15 2016-03-22 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9744208B2 (en) 2013-03-15 2017-08-29 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9956292B2 (en) 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
WO2017223177A1 (en) 2016-06-21 2017-12-28 Cedars-Sinai Medical Center Clinically efficacious anti-methanogenic compositions and uses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000180A2 (en) * 2001-06-20 2003-01-03 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
US20100055173A1 (en) * 2006-10-10 2010-03-04 Adel Penhasi Release of statins in the intestine
WO2014110090A1 (en) * 2013-01-08 2014-07-17 Jerome Schentag Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
: 5932-5939. Mohammad Faseleh Jahromi, et al. Lovastatin-Enriched Rice Straw Enhances Biomass Quality and Suppresses Ruminal Methanogenesis // Biomed Res Int- 2013.- 2013: 397934. *
Mohammad Faseleh jahromi, et al. Lovastatin in Aspergillus terreus: Fermented Rice Straw Extracts Interferes with Methane Production and Gene Expression in Methanobrevibacter smithii // BioMed Research International.- 2013.-(1-2):604721. *
Mohammad Faseleh jahromi, et al. Lovastatin in Aspergillus terreus: Fermented Rice Straw Extracts Interferes with Methane Production and Gene Expression in Methanobrevibacter smithii // BioMed Research International.- 2013.-(1-2):604721. (Carolina Santos Mello, et al. Methane production and small intestinal bacterial overgrowth in children living in a slum // World J Gastroenterol.- 2012.- 18(41): 5932-5939. *
Mohammad Faseleh Jahromi, et al. Lovastatin-Enriched Rice Straw Enhances Biomass Quality and Suppresses Ruminal Methanogenesis // Biomed Res Int- 2013.- 2013: 397934. Robert J. Basseri et al. Antibiotics for the Treatment of Irritable Bowel Syndrome // Gastroenterology & Hepatology. -2011. - Volume 7, Issue 7. -P. 455- 493. *
Robert J. Basseri et al. Antibiotics for the Treatment of Irritable Bowel Syndrome // Gastroenterology & Hepatology. -2011. - Volume 7, Issue 7. -P. 455- 493. А. К. Шаховская и др. Микробиологические аспекты в лечении запоров // Лечащий врач. - 2011. -[онлайн] https://www.lvrach.ru/2011/06/15435218/ [дата обращения: 18.03.2019]. Платошкин Э.Н. и др. ФУНКЦИОНАЛЬНЫЙ ЗАПОР (СООБЩЕНИЕ 1: ЭПИДЕМИОЛОГИЯ И ДИАГНОСТИКА) (ОБЗОР ЛИТЕРАТУРЫ) // Проблемы здоровья и экологии. -2013. -С. 63- 66. Черёмушкин С.В. ВЕДЕНИЕ БОЛЬНЫХ С СИНДРОМОМ РАЗДРАЖЕННОГО КИШЕЧНИКА // Медицинский совет. -2012. - С. 29-38. Savio C Reddymasu, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? // BMC Gastroenterol.- 2010.- 10: 23. М.В. Леонова. Новые лекарственные формы и системы доставки лекарственных средств: особенности пероральных лекарственных форм. Часть 2 // Клиническая фармакология. Лечебное дело.- 2009.- 3.- С. 18-26. *
Savio C Reddymasu, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? // BMC Gastroenterol.- 2010.- 10: 23. *
А. К. Шаховская и др. Микробиологические аспекты в лечении запоров // Лечащий врач. - 2011. -[онлайн] https://www.lvrach.ru/2011/06/15435218/ [дата обращения: 18.03.2019]. *
М.В. Леонова. Новые лекарственные формы и системы доставки лекарственных средств: особенности пероральных лекарственных форм. Часть 2 // Клиническая фармакология. Лечебное дело.- 2009.- 3.- С. 18-26. *
Платошкин Э.Н. и др. ФУНКЦИОНАЛЬНЫЙ ЗАПОР (СООБЩЕНИЕ 1: ЭПИДЕМИОЛОГИЯ И ДИАГНОСТИКА) (ОБЗОР ЛИТЕРАТУРЫ) // Проблемы здоровья и экологии. -2013. -С. 63- 66. *
Черёмушкин С.В. ВЕДЕНИЕ БОЛЬНЫХ С СИНДРОМОМ РАЗДРАЖЕННОГО КИШЕЧНИКА // Медицинский совет. -2012. - С. 29-38. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071673B2 (en) 2013-03-15 2024-08-27 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US11344501B2 (en) 2014-08-13 2022-05-31 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US11590102B2 (en) 2015-04-01 2023-02-28 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Also Published As

Publication number Publication date
EP3179983A1 (en) 2017-06-21
US20180289816A1 (en) 2018-10-11
AU2015301596A1 (en) 2017-02-02
JP2017528516A (ja) 2017-09-28
EP3179983A4 (en) 2018-01-10
IL250568B (en) 2021-05-31
US10668159B2 (en) 2020-06-02
US20190328885A1 (en) 2019-10-31
CN106687107B (zh) 2020-12-25
IL250568A0 (en) 2017-03-30
US20160045604A1 (en) 2016-02-18
RU2017106896A (ru) 2018-09-13
MX2017001971A (es) 2017-09-15
US11344501B2 (en) 2022-05-31
CN106687107A (zh) 2017-05-17
US10328151B2 (en) 2019-06-25
RU2017106896A3 (enExample) 2019-03-19
US20230036151A1 (en) 2023-02-02
US9956292B2 (en) 2018-05-01
BR112017002761A2 (pt) 2017-12-19
CA2955666A1 (en) 2016-02-18
AU2015301596B2 (en) 2020-04-16
KR102425303B1 (ko) 2022-07-25
KR20170041769A (ko) 2017-04-17
JP6667526B2 (ja) 2020-03-18
US20200323781A1 (en) 2020-10-15
WO2016025762A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
US20230036151A1 (en) Anti-methanogenic compositions and uses thereof
US20230398093A1 (en) Anti-methanogenic lovastatin analogs or derivatives and uses thereof
US20200390742A1 (en) Clinically efficacious anti-methanogenic compositions and uses
KR20150046310A (ko) 완화제 조성물 및 변비 및 관련 위장관 질병 및 증상 치료를 위한 방법
CN107708704A (zh) 微生物组调节剂和其相关用途
JP2023016863A (ja) メタン細菌に起因または関連する疾患および状態を診断、選択、および処置する方法
US11883537B2 (en) Sustained release solid dosage forms for modulating the colonic microbiome
Hubert et al. Development of a modified-release formulation of lovastatin targeted to intestinal methanogens implicated in irritable bowel syndrome with constipation
US20190277833A1 (en) Anti-methanogenic compositions
AU2018364617B2 (en) Oral rifamycin SV compositions
Kuzuya Effect of drugs on nutritional status and drug–nutrition interactions in older patients
EP3024461B1 (en) A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
HK40110949A (en) Oral rifamycin sv compositions
RU2290931C2 (ru) Лекарственное средство, снижающее микробную обсемененность helicobacter pylori у пациентов с язвенной болезнью двенадцатиперстной кишки в сочетании с описторхозом

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200814

NF4A Reinstatement of patent

Effective date: 20210823